Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ATOSthis companyAtossa Therapeutics, Inc.	$2.15	-2.19×	1.94×	0×	-1×	88.9%	0.0%	0.0%	0.0%	-88.4%	-94.4%	-39.1%	0×	1.19×	0×	5.53×	0.0%	1	-11.86	2	B-
CGTXCognition Therapeutics, Inc.	$0.69	-4.22×	2.87×	0×	-2.67×	-14.9%	0.0%	0.0%	0.0%	-68.5%	-136.9%	-25.0%	0.02×	1.56×	-3,676.85×	3.45×	0.0%	1	-0.97	2	C+
CLNNClene Inc.	$4.09	-2.22×	-3.29×	289.36×	-3.38×	-148.3%	78.5%	-11541.5%	-13086.5%	148.8%	-188.6%	-32.1%	-1.23×	-0.75×	-8.61×	0.83×	0.0%	2	-23.05	2	C
COYACoya Therapeutics, Inc.	$2.93	-4.57×	2.26×	12.21×	-2.37×	45.7%	99.7%	-255.0%	-267.1%	-49.3%	-46.0%	-11.1%	0×	2.21×	0×	8.5×	0.0%	3	8.76	1	D+
GLSIGreenwich LifeSciences, Inc.	$15.44	-14.69×	805.09×	0×	-14.37×	-99.2%	0.0%	0.0%	0.0%	-5480.5%	-5505.9%	-3.5%	0×	0.32×	0×	1.06×	0.0%	1	2.27	1	D+
IMMXImmix Biopharma, Inc.	$8.02	-5.88×	1.84×	0×	-2.69×	-63.4%	0.0%	0.0%	0.0%	-31.4%	-31.6%	-14.3%	0.01×	3.14×	0×	10.01×	0.0%	2	35.26	2	C+
Peer median	—	-4.57×	2.26×	0×	-2.69×	-63.4%	0.0%	0.0%	0.0%	-49.3%	-136.9%	-14.3%	0×	1.56×	0×	3.45×	0.0%	2	2.27	2	—